{{Rsnum
|rsid=1051669
|Gene=RAD52
|Chromosome=12
|position=913286
|Orientation=minus
|GMAF=0.2456
|Gene_s=RAD52
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.8 | 38.4 | 51.8
| HCB | 5.8 | 28.5 | 65.7
| JPT | 2.7 | 37.2 | 60.2
| YRI | 0.0 | 0.0 | 0.0
| ASW | 21.4 | 39.3 | 39.3
| CHB | 5.8 | 28.5 | 65.7
| CHD | 4.6 | 36.1 | 59.3
| GIH | 15.0 | 40.0 | 45.0
| LWK | 15.5 | 40.0 | 44.5
| MEX | 7.0 | 43.9 | 49.1
| MKK | 12.8 | 27.6 | 59.6
| TSI | 5.9 | 40.2 | 53.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=23209746
|Title=RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer
|OA=1
}}

{{PMID Auto
|PMID=25012956
|Title=A RAD52 genetic variant located in a miRNA binding site is associated with glioma risk in Han Chinese
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}